{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:15:44Z","timestamp":1784225744876,"version":"3.55.0"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,9,30]],"date-time":"2008-09-30T00:00:00Z","timestamp":1222732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contact Dermatitis"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:p><jats:bold>Background:\u2002<\/jats:bold> The CC\u2010chemokine receptor\u20101 (CCR1) is thought to be involved in recruitment of inflammatory cells in allergic contact dermatitis (ACD). CP\u2010481715 is a specific antagonist of CCR1.<\/jats:p><jats:p><jats:bold>Objectives:\u2002<\/jats:bold> To determine the inhibitory effects of CP\u2010418\u2003715 in ACD by evaluating the clinical signs and cellular infiltration in skin biopsies following epicutaneous nickel challenge in allergic subjects.<\/jats:p><jats:p><jats:bold>Subjects\/Methods:\u2002<\/jats:bold> In this phase 1\/2 study, 40 subjects were randomized to 5\u2003days of treatment in four parallel groups (placebo three times daily (TID), placebo once daily (QD), 1000\u2003mg CP\u2010418\u2003715 TID, and 3000\u2003mg CP\u2010418\u2003715 QD). Twenty\u2010four hours after the first drug administration, nickel sulfate patches were applied on subjects\u2019 backs and removed 48\u2003hours later.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Pretreatment with 1000\u2003mg CP\u2010481715 TID resulted in significant reductions in visual scores of the nickel reactions (<jats:italic>P\u2003<\/jats:italic>=\u20030.01). Instrumentally measured erythema tended to decrease in the CP\u2010481715\u2003mg TID group (<jats:italic>P\u2003<\/jats:italic>=\u20030.06). No differences were noted between the 3000\u2003mg CP\u2010481715\u2003mg QD group and pooled placebo. No significant differences were found for immunohistological cell counts. CP\u2010418\u2003715 was generally safe and well tolerated.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Blocking of CCR1 only partly inhibited clinical manifestations of ACD. Several chemokine receptors are likely relevant for the cellular influx observed in ACD lesions.<\/jats:p>","DOI":"10.1111\/j.1600-0536.2008.01365.x","type":"journal-article","created":{"date-parts":[[2010,8,12]],"date-time":"2010-08-12T12:57:10Z","timestamp":1281617830000},"page":"212-219","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of the effect of the specific CCR1 antagonist CP\u2010481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects"],"prefix":"10.1111","volume":"59","author":[{"given":"Jeanett","family":"Borregaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naitee","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Sonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Clucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,9,30]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04668.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1996.tb07603.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02126583"},{"key":"e_1_2_6_5_2","first-page":"349","article-title":"SDZ ASM 981 is the first non\u2010steroid that suppresses established nickel contact dermatitis elicited by allergen challenge","volume":"42","author":"Queille\u2010Roussel C","year":"2000","journal-title":"Contact Dermatitis"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.01.004"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612033454937"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63986-7"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M306875200"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746090-00003"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.8.715"},{"key":"e_1_2_6_12_2","first-page":"499","article-title":"CCR1 antagonists for treatment of autoimmune diseases","volume":"5","author":"Gladue R P","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.5.3141"},{"key":"e_1_2_6_14_2","first-page":"287","article-title":"Terminology of contact dermatitis","volume":"50","author":"International Contact Dermatitis Research Group (ICDRG)","year":"1970","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.5.3344"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.6.3392"},{"key":"e_1_2_6_17_2","first-page":"203","article-title":"Chemokine networks in inflammatory skin diseases","volume":"14","author":"Pastore S","year":"2004","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.3.1395"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0202-157"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.01771.x"}],"container-title":["Contact Dermatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0536.2008.01365.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0536.2008.01365.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T15:18:18Z","timestamp":1698765498000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0536.2008.01365.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,30]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1111\/j.1600-0536.2008.01365.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0536.2008.01365.x","archive":["Portico"],"relation":{},"ISSN":["0105-1873","1600-0536"],"issn-type":[{"value":"0105-1873","type":"print"},{"value":"1600-0536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,30]]}}}